StockData
Halozyme Therapeutics, Inc. logo

Halozyme Therapeutics, Inc. (HALO) company profile

HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3037% above fair value
$95.80−0.17 (-0.18%)

Close on Nov 18, 2026Market cap $10.87BP/E 28.3Yield –

About Halozyme Therapeutics

Biological Products, (No Diagnostic Substances), SIC 2836

Halozyme Therapeutics, Inc. is a biopharmaceutical company that develops and commercializes drug delivery platforms and specialized injection devices. The company's core offering is its ENHANZE technology, powered by the proprietary recombinant human hyaluronidase enzyme rHuPH20, which facilitates rapid subcutaneous delivery of injectable biologics and fluids to reduce patient treatment burden. Halozyme also develops the Hypercon and Surf Bio drug concentration technologies, alongside pressure-assisted auto-injectors and multi-dose pens. Its business model spans licensing proprietary delivery platforms to biopharmaceutical partners, collaborative drug-device product development, and the direct commercialization of proprietary offerings such as Hylenex recombinant and XYOSTED. Customers and collaborators include major global pharmaceutical companies, healthcare providers, and patients.

The company operates from its principal executive offices and research facilities situated in San Diego, California. Halozyme licenses and collaborates with international biopharmaceutical partners that market therapies and advance programs across multiple global markets, including the United States, Europe, Canada, Japan, and China.

Summary of the business section of Halozyme Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Halozyme Therapeutics, Inc.
Founded
1998
Headquarters
San Diego, CA
Address
12390 El Camino Real 92130
Phone
(858) 794-8889
Employees
423, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst& Young LLP, San Diego, California

Stock & identifiers

Ticker
HALO
Exchange
Nasdaq
IPO date
Mar 16, 2004
Shares outstanding
113M, Jul 31, 2026
Public float
$4.50B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1159036
CUSIP
40637H109
ISIN
US40637H1095
FIGI
BBG000CZ8W54
Share class FIGI
BBG001SGX585
LEI
529900242I3SV9AGM753
EIN
88-0488686

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Helen TorleyPRESIDENT AND CEO, Director767,780
David A. RamsayEVP, PRESIDENT, DRUG DELIVERY10,000
Darren SnellgroveSVP, Chief Financial Officer–
Mark Howard SnyderSVP, CHIEF LEGAL OFFICER52,644
Cortney CaudillSVP, CHIEF OPERATING OFFICER15,912
Nicole LaBrosseSVP, CHIEF FINANCIAL OFFICER42,102
Michael J. LaBarreSVP, CHIEF TECHNICAL OFFICER173,756
Bernadette ConnaughtonDirector42,294
Matthew L. PosardDirector53,609
James M. DalyDirector1,169
Dannielle AppelhansDirector1,161
Mahesh KrishnanDirector14,462
Jeffrey William HendersonDirector36,572
Barbara Gayle DuncanDirector23,715
James Paul LangDirector4,685
Akiko Moni MiyashitaDirector24,937
Connie MatsuiDirector183,035

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$23.17M$39.73M$3.59M$158$125
FY2024$12.74M$20.75M$4.22M$112$93
FY2023$11.82M-$3.61M$3.57M$87$94
FY2022$9.70M$22.82M$2.42M$133$90
FY2021$7.45M$5.99M$2.40M$94$100
FY2020$6.52M$24.37M$1.81M$241$126

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Helen I. Torley
President and Chief Executive Officer
$1.00M$19.35M$1.65M$1.15M$18.56K$23.17M+82%
Nicole LaBrosse
Senior Vice President, Chief Financial Officer
$604.19K$2.98M$525.00K$462.20K$12.29K$4.58M+9%
Mark Snyder
Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary
$619.00K$2.98M$525.00K$394.61K$17.82K$4.53M-16%
Cortney Caudill
Senior Vice President, Chief Operating Officer
$561.00K$1.74M$512.54K$382.50K$9.23K$3.20M–
Michael J. LaBarre
Former Senior Vice President, Chief Technical Officer
$120.32K$1.57M$276.45K–$90.24K$2.05M-32%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of February 10, 2026, we had 423 full-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
May 24, 2022Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Apr 26, 2022Tender offerThird-party tender offer for the company's shares
Nov 2, 2021Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 20, 2007Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 9, 2007ListingRegistration of securities on an exchange (Form 8-A)
May 9, 2007DelistingNotice of delisting from exchange (Form 25)
Jun 29, 2006Auditor changeChange in certifying accountant (8-K Item 4.01)
Oct 27, 2004ListingRegistration of securities on an exchange (Form 8-A)
Mar 12, 2004Name changeName changed from GLOBAL YACHT SERVICES INC to HALOZYME THERAPEUTICS INC
May 16, 2003Late filingNotification of late filing
Aug 14, 2002Late filingNotification of late filing

See a number that looks wrong?